Krystal Biotech, Inc.
KRYSDrugs in Pipeline
7
Phase 3 Programs
3
Upcoming Catalysts
3
Next Catalyst
Dec 15, 2026
37wMarket Overview
Stock performance and key metrics
3 upcoming, 2 past
Open Label Topical Beremagene Geperpavec (B-VEC)
Dystrophic Epidermolysis Bullosa
Topical beremagene geperpavec
Dystrophic Epidermolysis Bullosa
KB803
Dystrophic Epidermolysis Bullosa
KB801
Neurotrophic Keratitis
Opdualag
Cancer
KB707
Lung Cancer, Non-small Cell
KB304
Wrinkles in Decolletage
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Open Label Topical Beremagene Geperpavec (B-VEC) | Phase 3 | Dystrophic Epidermolysis Bullosa | - | - |
Topical beremagene geperpavec | Phase 3 | Dystrophic Epidermolysis Bullosa | - | - |
KB803 | Phase 3 | Dystrophic Epidermolysis Bullosa | - | - |
KB801 | Phase 2 | Neurotrophic Keratitis | - | - |
Opdualag | Phase 2 | Cancer | - | - |
KB707 | Phase 2 | Lung Cancer, Non-small Cell | - | - |
KB304 | Phase 2 | Wrinkles in Decolletage | - | - |
Dystrophic Epidermolysis Bullosa
3 drugs in this indication
Lung Cancer, Non-small Cell
1 drug in this indication
Neurotrophic Keratitis
1 drug in this indication
Wrinkles in Decolletage
1 drug in this indication
Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)